Pacific Edge slumps 89.9% on Novitas decision

Pacific Edge slumps 89.9% on Novitas decision
The company still believes that it can still deliver. (Image: Pacific Edge).
Rebecca Howard
Shares of Pacific Edge plunged 89.9% on news that Medicare coverage of Cxbladder tests in the US is expected to cease from July 17.The shares resumed trading at 5 cents, having been halted on Tuesday at 49.5 cents while management worked through the implications of the decision.That wiped out $360.6 million of value as investors put a market price of $40.5m on Pacific Edge.  Over the coming days Pacific Edge will seek to explore all available legal options, including a potential appeal, with its US-based lawyers, the company said.A so-call...

More Markets

Key says insider trading claim without merit
Markets

Key says insider trading claim without merit

US claimants target the company's directors over share prices and trading.

Positive Gentrack result gives sharemarket a boost
Markets Market close

Positive Gentrack result gives sharemarket a boost

The S&P/NZX 50 Index closed at 11,720.8, up 35.92 points or 0.31%.

Comvita opens books to bidder, cuts costs
Markets

Comvita opens books to bidder, cuts costs

The honey firm is finding a further $10m in costs to cut as it also cuts back guidance.

The Warehouse forced back to basics
Markets

Rebecca Stevenson: The Warehouse forced back to basics

While its rivals were fighting for customers, The Warehouse obsessed about itself.